Jeffrey S. Martini - 13 Dec 2024 Form 3 Insider Report for PALVELLA THERAPEUTICS, INC. (PVLA)

Role
Chief Scientific Officer
Signature
/s/ Kathleen A. McGowan, Attorney-in-Fact
Issuer symbol
PVLA
Transactions as of
13 Dec 2024
Net transactions value
$0
Form type
3
Filing time
16 Dec 2024, 19:42:34 UTC
Next filing
10 Feb 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PVLA Stock Option (right to buy) 13 Dec 2024 Common Stock 32,272 $9.08 Direct F1
holding PVLA Stock Option (right to buy) 13 Dec 2024 Common Stock 10,213 $9.79 Direct F2
holding PVLA Stock Option (right to buy) 13 Dec 2024 Common Stock 18,541 $9.79 Direct F2
holding PVLA Stock Option (right to buy) 13 Dec 2024 Common Stock 13,281 $7.53 Direct F3
holding PVLA Stock Option (right to buy) 13 Dec 2024 Common Stock 6,606 $7.53 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option is fully vested.
F2 The stock option vests in equal monthly installments over a forty-eight month period. The option was granted on February 23, 2023.
F3 The stock option vests in equal monthly installments over a forty-eight month period. The option was granted on May 28, 2024.